Table 1.
Baseline Characteristics and Outcomes of the Development and Validation Cohortsa
| Characteristic | Development Cohort (n=3,816) | Validation Cohort (n=3,232) | P Value |
|---|---|---|---|
| Demographics | |||
| Age, y | 65.4 (19.4) | 63.3 (19.0) | <.001 |
| White | 3,492 (91.5) | 2,957 (91.5) | >.99 |
| Men | 1,705 (44.7) | 1,417 (43.8) | >.99 |
| Admission to medical unit | 2,345 (61.4) | 1,747 (54.1) | <.001 |
| Baseline creatinine, mg/dL | 1.0 (0.4) | 1.1 (0.9) | .73 |
| Charlson Comorbidity Index | 4.8 (3.8) | 4.3 (3.0) | .01 |
| Length of stay, d | 3.9 (4.0) | 3.3 (3.5) | .13 |
| Renal outcomes | |||
| Any AKI | 393 (10.3) | 351 (10.8) | .48 |
| Moderate-severe AKI | 72 (1.9) | 54 (1.7) | .27 |
| Renal replacement | 15 (0.4) | 27 (0.8) | .02 |
Abbreviation: AKI=acute kidney injury.
a
Values are mean (SD) or No. of patients (%).